{"id":450,"date":"2015-04-01T12:41:56","date_gmt":"2015-04-01T12:41:56","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=450"},"modified":"2025-05-05T18:00:55","modified_gmt":"2025-05-05T12:30:55","slug":"antibody-drug-conjugate-and-big-pharmaceutical-companies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies","title":{"rendered":"Antibody-Drug Conjugate and Big Pharmaceutical Companies"},"content":{"rendered":"<blockquote>\n<p style=\"text-align: center;\"><strong>Antibody Drug Conjugate and Big Pharmaceutical Companies Boom<\/strong><\/p>\n<\/blockquote>\n<p>Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success, more companies are looking to produce these drugs. Although antibody-drug conjugates show promise in the development of effective cancer therapies, there are still a variety of challenges involved in enabling the safe manufacture of these hazardous drugs. ADC\u2019s continues to gain popularity but the market is in infant stage with only 3 drugs approved by U.S. FDA.<\/p>\n<ol>\n<li><strong>Mylotarg <\/strong>from<strong> Wyeth (now Pfizer)<\/strong> was the 1<sup>st<\/sup> drug approved for the treatment of acute myeloid leukaemia back in 2000 but was withdrawn a decade later.<\/li>\n<li><strong>Adcetris<\/strong> (brentuximab vedotin) from <strong>Seattle Genetics<\/strong> was approved by the FDA in 2011 for the treatment of Hodgkin\u2019s lymphoma and systemic anaplastic large cell lymphoma.<\/li>\n<li><strong>Genentech\u2019s Kadcyla<\/strong> (ado-trastuzumab emtansine) was given FDA approval in early 2013. ImmunoGen holds patents on Kadcyla and how it is manufactured, and receive royalties from Roche on its sales.<\/li>\n<\/ol>\n<p>More than 264 Antibody-drug conjugates are under pipeline and as the large numbers of pharmaceutical companies are involved in antibody-drug conjugates market, therefore it is expected that this market will grow rapidly.<\/p>\n<p><img decoding=\"async\" class=\"  wp-image-452 aligncenter\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/daljdljadl.jpg?w=300\" alt=\"DALJDljADL\" width=\"417\" height=\"250\" \/>Although the market now has the presence of many large pharmaceutical companies, the technology lies with only a few. Seattle Genetics and ImmunoGen are the pioneers in technology licensing, with most drugs using their technology.<\/p>\n<p>The future of ADCs in the biopharmaceutical market will ultimately depend on their clinical success. Companies and researchers are seeking to meet that challenge by optimizing the selection of all the components in the ADC\u2014the antibody, linker, and cytotoxin\u2014and successfully combining manufacturing techniques for both high- potency APIs and biologics. Earlier unsuccessful attempts to generate ADCs with therapeutic value have emphasized the important role each component plays in determining the efficacy and safety of the final ADC.<\/p>\n<p>Since ADC\u2019s are highly complex to manufacture, it provides unique opportunities and challenges to Contract Manufacturers Organizations (CMOs) and biopharmaceutical companies seeking CMP partners for their ADC candidates.<\/p>\n<p>In some cases, three separate CMOs are utilized- one for the chemical linker, one for the antibody and one for the highly potent drug. Then, everything is shipped to someone else for conjugation.<\/p>\n<p>Some CMO\u2019s which offer ADC Conjugation services include Lonza, Laureate Biopharma, Piramal Healthcare Pharma Solutions, Abbott contracts manufacturing, Aquitaine Pharm International, etc.<\/p>\n<p>ADCs are sometimes described as armed antibodies and their cytotoxic components as warheads. Whether ADCs will prove to be an effective weapon against cancer or other diseases has yet to be seen as more are tested in the clinic.<\/p>\n<p><em>By Shriya Sahni, Associate Analyst, DelveInsight<\/em><\/p>\n<p>For more information on this Report, please mail at info@delveInsight.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antibody Drug Conjugate and Big Pharmaceutical Companies Boom Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success, more companies are looking to produce these drugs. Although antibody-drug conjugates show promise in the development of effective cancer therapies, there are still a variety of challenges involved in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[48,55,62,65,73,78,90,113,128,170,184,204,312,343,350,361,414,460,465,468,487,534,558],"industry":[17225],"therapeutic_areas":[17235,17228],"class_list":["post-450","post","type-post","status-publish","format-standard","hentry","category-articles","tag-264-antibody-drug-conjugates","tag-abbott-contracts-manufacturing","tag-adcetris","tag-ado-trastuzumab-emtansine","tag-ambryx","tag-antibody-drug-conjugates","tag-aquitaine-pharm-international","tag-bioalta","tag-brentuximab-vedotin","tag-cmos","tag-contract-manufacturers-organizations","tag-delveinsight","tag-immunogen","tag-kadcyla","tag-laureate-biopharma","tag-lonza","tag-mylotarg","tag-pfizer","tag-pharma-companies","tag-pharma-solutions","tag-piramal-healthcare","tag-seattle-genetics","tag-technology-assessments","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Antibody Drug Conjugate Market Gains Momentum | DelveInsight<\/title>\n<meta name=\"description\" content=\"Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibody Drug Conjugate Market Gains Momentum | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-04-01T12:41:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T12:30:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/daljdljadl.jpg?w=300\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antibody Drug Conjugate Market Gains Momentum | DelveInsight","description":"Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies","og_locale":"en_US","og_type":"article","og_title":"Antibody Drug Conjugate Market Gains Momentum | DelveInsight","og_description":"Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success.","og_url":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-04-01T12:41:56+00:00","article_modified_time":"2025-05-05T12:30:55+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/daljdljadl.jpg?w=300","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies","url":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies","name":"Antibody Drug Conjugate Market Gains Momentum | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/daljdljadl.jpg?w=300","datePublished":"2015-04-01T12:41:56+00:00","dateModified":"2025-05-05T12:30:55+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-and-big-pharmaceutical-companies#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/daljdljadl.jpg?w=300","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/04\/daljdljadl.jpg?w=300"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">264 Antibody-drug conjugates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Abbott contracts manufacturing<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Adcetris<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ado-trastuzumab emtansine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Ambryx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Aquitaine Pharm International<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">BioAlta<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">brentuximab vedotin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CMOs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Contract Manufacturers Organizations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">ImmunoGen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Kadcyla<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Laureate Biopharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lonza<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Mylotarg<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharma Companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharma Solutions<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Piramal Healthcare<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Seattle Genetics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">technology assessments<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">264 Antibody-drug conjugates<\/span>","<span class=\"advgb-post-tax-term\">Abbott contracts manufacturing<\/span>","<span class=\"advgb-post-tax-term\">Adcetris<\/span>","<span class=\"advgb-post-tax-term\">ado-trastuzumab emtansine<\/span>","<span class=\"advgb-post-tax-term\">Ambryx<\/span>","<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/span>","<span class=\"advgb-post-tax-term\">Aquitaine Pharm International<\/span>","<span class=\"advgb-post-tax-term\">BioAlta<\/span>","<span class=\"advgb-post-tax-term\">brentuximab vedotin<\/span>","<span class=\"advgb-post-tax-term\">CMOs<\/span>","<span class=\"advgb-post-tax-term\">Contract Manufacturers Organizations<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">ImmunoGen<\/span>","<span class=\"advgb-post-tax-term\">Kadcyla<\/span>","<span class=\"advgb-post-tax-term\">Laureate Biopharma<\/span>","<span class=\"advgb-post-tax-term\">Lonza<\/span>","<span class=\"advgb-post-tax-term\">Mylotarg<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Pharma Companies<\/span>","<span class=\"advgb-post-tax-term\">Pharma Solutions<\/span>","<span class=\"advgb-post-tax-term\">Piramal Healthcare<\/span>","<span class=\"advgb-post-tax-term\">Seattle Genetics<\/span>","<span class=\"advgb-post-tax-term\">technology assessments<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Apr 1, 2015","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Apr 1, 2015 12:41 pm","modified":"Updated on May 5, 2025 6:00 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=450"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/450\/revisions"}],"predecessor-version":[{"id":31681,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/450\/revisions\/31681"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=450"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=450"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}